Interview with CEO Ulrich Krasilnikoff and CSO Andreas Kjær on highlights from FY 2022 and update on pipeline
Interview with CEO Ulrich Krasilnikoff and CSO Andreas Kjær on highlights from FY 2022 and update on pipeline.
CEO Ulrich Krasilnikoff gave investors more flavour on potential partners and CSO Andreas Kjær gave an in depth update on the pipeline and especially the two phase ll projects.
Listen here: https://www.inderes.dk/videos/curasight-praesentation-af-arsrapport-2022-og-pipeline-update
Disclaimer:
HC Andersen Capital receives payment from Curasight for a Digital IR/Corporate Visibility subscription agreement. /Claus Thestrup 9:00 AM 02-28-2023.
Curasight is a Danish biotech company focusing on developing and improving the detection and treatment of cancer in a more gentle and efficient way. The company has two pipeline products that both use radionuclide (nuclear medicine) to facilitate better diagnosis and treatment of various cancer types; uTRACE use the so-called uPAR as a biomarker to diagnose the aggressiveness of cancer, and uTREAT use the uPAR as a attachment to treat the cancer. Based on good phase 2 data that has already been collected or will be in the first half of 2022, Curasight is expected to prepare phase 3 for uTRACE later in 2022 and 2023 for the following four cancer types: prostate, brain, neuroendocrine, and head and neck cancer.
Read more on company page